The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.

被引：1
|
作者：
Mustacchi, Giorgio
Cazzaniga, Marina Elena
Romagnoli, Emanuela
Montemurro, Filippo
De laurentiis, Michele
Riccardi, Ferdinando
Turletti, Anna
Beano, Alessandra
De Angelis, Claudia
Graziano, Vincenzo
Livi, Lorenzo
Del Mastro, Lucia
Biganzoli, Laura
Garrone, Ornella
De Placido, Sabina
Marchetti, Paolo
Pronzato, Paolo
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1055
引用
收藏
页数：6
相关论文
共 50 条
  • [1] First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study.
    Pronzato, Paolo
    Mustacchi, Giorgio
    Giordano, Monica
    Garrone, Ornella
    Del Mastro, Lucia
    Natoli, Clara
    Turletti, Anna
    Romagnoli, Emanuela
    Bologna, Alessandra
    Mocerino, Carmela
    Alu, Massimiliano
    De Angelis, Claudia
    Aversa, Caterina
    Arpino, Grazia
    Taverniti, Cristiana
    Biganzoli, Laura
    Meattini, Icro
    Piezzo, Michela
    Cazzaniga, Marina Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13-AMBRA Study
    Cazzaniga, M.
    Mustacchi, G.
    Giordano, M.
    Garrone, O.
    Donadio, M.
    del Mastro, L.
    Livi, L.
    Natoli, C.
    Michelotti, A.
    Turletti, A.
    Ferdinando, R.
    De laurentiis, M.
    Marchetti, P.
    Montemurro, M.
    Romagnoli, E.
    De Placido, S.
    Pronzato, P.
    Biganzoli, L.
    Bisagni, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13-AMBRA study
    Mustacchi, G.
    Cazzaniga, M.
    Bria, E.
    Bisagni, G.
    Biganzoli, L.
    Pronzato, P.
    De Placido, S.
    Romagnoli, E.
    Montemurro, F.
    Marchetti, P.
    De laurentiis, M.
    Riccardi, F.
    Turletti, A.
    Michelotti, A.
    Natoli, C.
    Livi, L.
    Del Mastro, L.
    Donadio, M.
    Garrone, O.
    Giordano, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] NAB-PACLITAXEL (NAB-P) IN HER2-VE ADVANCED BREAST CANCER (ABC) PATIENTS (PTS): FOCUS ON LUMINAL CANCERS. RESULTS FROM GIM13-AMBRA STUDY
    Cazzaniga, Marina Elena
    Mustacchi, Giorgio
    Bria, Emilio
    Bisagni, Giancarlo
    Biganzoli, Laura
    Pronzato, Paolo
    De Placido, Sabino
    Romagnoli, Emanuela
    Montemurro, Filippo
    Marchetti, Paolo
    De laurentis, Michelino
    Riccardi, Ferdinando
    Turletti, Anna
    Michelotti, Andrea
    Natoli, Clara
    Livi, Lorenzo
    Del Mastro, Lucia
    Donadio, Michela
    Garrone, Ornella
    Giordano, Monica
    BREAST, 2017, 36 : S51 - S52
  • [5] Impact of fulvestrant utilization on prognostic outcome among patients with HR+ve/HER2-ve metastatic breast cancer: Results from a real-world dataset
    Dawood, S.
    Hernandez-Ibarburu, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S374 - S375
  • [6] 2Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13-AMBRA study
    Mustacchi, G.
    Cazzaniga, M.
    Giordano, M.
    Garrone, O.
    Donadio, M.
    Del Mastro, L.
    Livi, L.
    Natoli, C.
    Michelotti, A.
    Turletti, A.
    Riccardi, F.
    Marchetti, P.
    Montemurro, F.
    Romagnoli, E.
    De Placido, S.
    Biganzoli, L.
    Bisagni, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study.
    Mustacchi, Giorgio
    Cazzaniga, Marina Elena
    Giordano, Monica
    Garrone, Ornella
    Beano, Alessandra
    Del Mastro, Lucia
    Livi, Lorenzo
    Iezzi, Laura
    Michelotti, Andrea
    Turletti, Anna
    Riccardi, Ferdinando
    De laurentiis, Michele
    Marchetti, Paolo
    Biganzoli, Laura
    Montemurro, Filippo
    Romagnoli, Emanuela
    De Placido, Sabino
    Pronzato, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13-AMBRA" Italian study
    Mustacchi, G.
    Cazzaniga, M. E.
    Biganzoli, L.
    De Laurentiis, M.
    Del Mastro, L.
    De Placido, S.
    Donadio, M.
    Garrone, O.
    Giordano, M.
    Latini, L.
    Livi, L.
    Marchetti, P.
    Michelotti, A.
    Montemurro, F.
    Natoli, C.
    Pronzato, P.
    Riccardi, F.
    Turletti, A.
    CANCER RESEARCH, 2017, 77
  • [9] Fulvestrant (FUL) as first-line therapy in HR1ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study
    Pronzato, P.
    Mustacchi, G.
    Riccardi, F.
    Turletti, A.
    Michelotti, A.
    Natoli, C.
    Livi, L.
    Del Mastro, L.
    Donadio, M.
    Garrone, O.
    Giordano, M.
    De laurentiis, M.
    Marchetti, P.
    Montemurro, F.
    Romagnoli, E.
    De Placido, S.
    Biganzoli, L.
    Cazzaniga, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Choices of first-line therapy in her2-ve advanced breast cancer (abc) patients (pts). prelimary results of the gim-13-ambra study
    Cazzaniga, M. E.
    Mustacchi, G.
    Giordano, M.
    Garrone, O.
    Donadio, M.
    Del Mastro, L.
    Livi, L.
    Natoli, C.
    Michelotti, A.
    Turletti, A.
    Riccardi, F.
    Paolo, P.
    De Placido, S.
    De laurentiis, M.
    Marchetti, P.
    Montemurro, F.
    ANNALS OF ONCOLOGY, 2016, 27
12345